Trial Profile
A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
- 19 Dec 2023 Status changed from active, no longer recruiting to completed.
- 16 Feb 2023 This trial has been completed in Ireland, according to European Clinical Trials Database record.
- 15 Feb 2023 This trial has been completed in Germany according to European Clinical Trials Database record.